Рак предстательной железы: когда нужна терапия тестостероном?
- Авторы: Сухих С.О.1, Васильев А.О.1, Говоров А.В.1, Пушкарь Д.Ю.1
-
Учреждения:
- ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России
- Выпуск: Том 20, № 7 (2018)
- Страницы: 8-10
- Раздел: Статьи
- URL: https://journals.rcsi.science/2075-1753/article/view/94965
- DOI: https://doi.org/10.26442/2075-1753_2018.7.8-10
- ID: 94965
Цитировать
Полный текст
Аннотация
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Сергей Олегович Сухих
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России
Email: docsukhikh@gmail.com
аспирант каф. урологии 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
Александр Олегович Васильев
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России
Email: alexvasilyev@me.com
канд. мед. наук, ассистент каф. урологии 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
Александр Викторович Говоров
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России
Email: dr.govorov@gmail.com
д-р мед. наук, проф. каф. урологии 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
Дмитрий Юрьевич Пушкарь
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России
Email: pushkardm@mail.ru
чл.-кор. РАН, проф., зав. каф. урологии 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
Список литературы
- Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006; 50 (5): 935.
- Fernández-Miró M, Chillarón J.J, Pedro-Botet J. Testosterone deficiency, metabolic syndrome and diabetes mellitus. Med Clin 2016; 146 (2): 69-73.
- Lytton B. Prostate cancer: a brief history and the discovery of hormonal ablation treatment. J Urol 2001; 3: 37-8.
- Surampudi P.N, Wang C, Swerdloff R. Hypogonadism in the aging male diagnosis, potentials benefits, and risks of testosterone re- placement therapy. Int J Endocrinol 2012; 2 (2): 23-34.
- SEER Cancer Statistics Factsheets: Prostate Cancer. National Cancer Institute; Bethesda, MD, USA. Available at: http://seer.cancer.gov/statfacts/html/prost.html
- Zhou Y, Bolton E.C, Jones J.O. Androgens and androgen receptor signaling in prostate tumorigenesis. J Mol Endocrinol 2015; 54 (1): 15-29.
- Huggins C, Hodges C.V. The effect of castration, of estrogen and of androgen injection on serum phosphatase on metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
- Brooke G.N, Bevan C.L. The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 2009; 10 (1): 18-25.
- Prehn R.T. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999; 59: 4161-4.
- DeVore N.M, Scott E.E. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature 2012; 22: 116.
- Zhou Y, Otto-Duessel M, He M et al. Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue. J Mol Endocrinol 2013; 51: 143-53.
- Traish A.M, Miner M.M, Morgentaler A et al. Testosterone deficiency. Am J Med 2011; 124 (7): 578-87.
- Stattin P, Lumme S, Tenkanen L et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Can 2004; 108: 418-24.
- Yassin D-J, Manka L, Yassin A et al. Effect of testosterone treatment in hypogonadal men on prostate cancer risk: results of a prospective comparative study - 8 years follow-up analysis to age-matched controls. ASCO Meeting Abstracts 2014.
- Agarwal P.K, Oefelein M.G. Testerone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533-6.
- Khera M, Grober E.D, Najari B et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009; 6: 1165-70.
- Pastuszak A.W, Pearlman A.M, Lai W.S et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013; 190: 639-44.
- Bellefqih S, Hadadi K, Mezouri I et al. Combined radiation therapy and androgen deprivation in the management of prostate cancer: Where do we stand? Cancer Radiother 2016; 8.
- Pastuszak A.W, Pearlman A.M, Godoy G et al. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res 2013; 25: 24-8.
- Song W, Khera M. Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro. Asian J Androl 2014; 16: 864.
- American Cancer Society recommendations for prostate cancer early detection. Available at: https: //www.cancer.org/cancer/prostate-cancer/early-detection/acs-recommendations.html
- Khera M, Crawford D, Morales A et al. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 2014; 65: 115-23.
- Kühn C.M, Strasser H, Romming A et al. Testosterone Replacement Therapy in Hypogonadal Men Following Prostate Cancer Treatment: A Questionnaire-Based Retrospective Study among Urologists in Bavaria, Germany. Urol Int 2015; 95: 153-9.
- Sarosdy M.F. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007; 109: 536-41.
- Balbontin F.G, Moreno S.A, Bley E et al. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int 2014; 114: 125-30.
- Pastuszak A.W, Khanna A, Badhiwala N et al. Testosterone therapy after radiation therapy for low, intermediate, and high risk prostate cancer. J Urol 2015; 194: 1271-6.
- Kaplan A.L, Trinh Q.D, Sun M et al. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. J Sex Med 2014; 11: 1063-70.
- Kaplan A.L, Lenis A.T, Shah A et al. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis. J Sex Med 2015; 12: 374-80.
- Morgentaler A, Rhoden E.L. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/ml or less. Urology 2006; 68: 1263-7.
- Kacker R, Mariam H, San Francisco I.F et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl 2016; 18 (1): 16-20.